A phase II trial of pemetrexed plus gemcitabine in locally advanced and/ or metastatic transitional cell carcinoma of the urothelium

Annals of Oncology

Volumn 17, Issue 10, 2006, Pages 1533-1538

  von der Maase, H ^a   Lehmann, J ^b   Gravis, G ^c   Joensuu, H ^d   Geertsen, P F ^e   Gough, J ^f   Chen, G ^f   Kania, M ^f  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b SAARLAND UNIVERSITY   (Germany)

^c INSTITUT PAOLI CALMETTES   (France)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Bladder cancer; Gemcitabine; Pemetrexed; Urothelial cancer

Indexed keywords

AMINOTRANSFERASE; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; SEPSIS; SEX DIFFERENCE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CARCINOMA; UROTHELIUM; VISCERAL METASTASIS; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 33749605418     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl154     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
3. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
4. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
5. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
6. Paz-Ares L, Ciruelos E, Garcia-Carbonero R et al. Pemetrexed in bladder, head and neck, and cervical cancers. Semin Oncol 2002; 29 (Suppl 18): 69-75.
7. Sweeney CJ, Roth B, Kaufman D et al. Phase II study of pemetrexed (PEM) for second-line treatment of transitional cell cancer (TCC) of the bladder (abstract). Proc Am Soc Clin Oncol 2003; 22: 411.
8. von der Maase H. Pemetrexed in transitional cell carcinoma of the urothelium. Oncol 2004; 18 (13 Suppl 8): 48-50.
9. Adjei AA. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. Semin Oncol 2002; 29 (6 Suppl 18): 30-346.
10. von der Maase H: Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 3: 11-19.
11. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
12. Arbuck SG, Ivy SP, Setser A et al. The Revised Common Toxicity Criteria: Version 2.0. CTEP Website. http://ctep.info.nih.gov.
13. Stadler WM, Kuzel T, Roth B et al. Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-3398.
14. Moore MJ, Tannock IF, Ernst DS et al. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441-3445.
15. Lorries V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-1212.
16. Gebbia V, Testa A, Borsellino N et al. Single agent 29,29-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: A phase II study. Clin Ter 1999; 150: 47-52.
17. Tonkinson, JL, Worzalla JF, Teng C-H, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-3676.
18. Tesei A, Ricotti L, De Paola F et al. In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 2002; 8: 233-239.
19. Adjei AA, Nair S, Reuter N et al. Pemetrexed (Pem)/gemcitabine (Gem) as frontline therapy for advanced NSCLC: A randomized, phase II trial of three schedules. J Clin Oncol 2004; 22 (14S) (Abstr 7070).
20. Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118.